why choose us

First received: July 28, 2022

Clinical Trial: Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

Study Status: Completed

Recruit Status: RECRUITING

Condition: Down Syndrome

Study Type: INTERVENTIONAL


Official Title: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

Brief Summary: This trial protocol is designed to evaluate primarily whether the use of sargramostim (recombinant human GM-CSF), administered five days per week for four consecutive weeks (20 treatment days), will be well tolerated by and safe for use in young adult participants with Down syndrome.

Read more